Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00857220 · ClinicalTrials.gov registry record · Phase 3
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
A Phase 3 study of Insomnia and Attention Deficit Hyperactivity Disorder, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 304
- Enrollment target
- 20
- Study locations
NCT00857220: Completed Phase 3 study of Insomnia and Attention Deficit Hyperactivity Disorder, sponsored by Sumitomo Pharma America.
NCT00857220 is a Phase 3 study of Insomnia and Attention Deficit Hyperactivity Disorder that has completed, run by Sumitomo Pharma America. The registered enrollment target is 304 participants, above the 168-participant average among 151 other Insomnia trials with a reported enrollment target (81% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00857220, a Phase 3 study of Insomnia and Attention Deficit Hyperactivity Disorder, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 304 participants
- Enrollment target
- 20
- Study locations
Study Summary
A multicenter study to evaluate the safety of eszopiclone in children (6 11 years of age, inclusive) and adolescents (12 17 years of age, inclusive) with attention deficit/hyperactivity disorder (ADHD) associated insomnia.
Conditions Studied
Interventions
- DRUG eszopiclone
Study Locations (20)
California
- AV Institute, Inc. - Carson
- Clinical Innovations, Inc. - Costa Mesa
- Behavioral Research Specialists, LLC - Glendale
- Sun Valley Research Center - Imperial
- Excell Research, Inc. - Oceanside
- North County Clinical Research (NCCR) - Oceanside
- Pacific Clinical Research Medical Group - Orange
- SDS Clinical Trials, Inc. - Orange
- Clinical Innovations, Inc. - Riverside
- Artemis Institute for Clinical Research - San Diego
- Clinical Innovations - San Diego
- Neuropsychiatric Research Center of Orange County - Santa Ana
- Apex Research Institute - Santa Ana
- Clinical Innovations, Inc. - Santa Ana
- Elite Clinical Trials, Inc. - Wildomar
Florida
- Sarkis Clinical Trials - Gainesville
- MD Clinical - Hallandale
Arizona
- REM Medical Clinical Research - Tucson
Arkansas
- Clinical Study Centers, LLC - Little Rock
Colorado
- Delta Waves, Inc. - Colorado Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 304 participants |
| Start Date | 2009-05 |
| Est. Completion | 2011-10 |
| Phase | Phase 3 |
What the finished NCT00857220 record still lists
NCT00857220 is an interventional study that assigns participants to a tested intervention. The registered 304 participants enrollment target is mid-sized for trials with a published cap, above the 168-participant average among 151 other Insomnia trials with a reported enrollment target (81% higher).
The record links to 2 conditions, with Insomnia appearing as the primary indexed condition, and to 1 intervention - of which eszopiclone is the first listed.
NCT00857220 names 20 study sites across 5 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT00857220 about?
NCT00857220 is a clinical study titled "Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia". A multicenter study to evaluate the safety of eszopiclone in children (6 11 years of age, inclusive) and adolescents (12 17 years of age, inclusive) with attention deficit/hyperactivity disorder (ADHD) associated insomnia.
What is the current status of trial NCT00857220?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 304 participants. The study started on 2009-05. Estimated completion is 2011-10.
What conditions does trial NCT00857220 study?
This clinical trial studies the following conditions: Insomnia, Attention Deficit Hyperactivity Disorder.
What interventions are being tested in trial NCT00857220?
The interventions under investigation include: eszopiclone (DRUG).
Who is sponsoring clinical trial NCT00857220?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00857220 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Insomnia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00857220's enrollment target sits among peer trials
304 23rd of 151 higher than 129 of 151 other Insomnia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Insomnia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)
RECRUITING · Phase 3
-
National Adaptive Trial for PTSD Related Insomnia
ACTIVE NOT RECRUITING · Phase 3
-
Short and Long-Term Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis
COMPLETED · Phase 3
-
A Study of Eszopiclone in Subjects With Insomnia Related to Major Depressive Disorder
COMPLETED · Phase 3
-
Registry to Collect Information on Pregnancy, Neonatal, and Infant Outcomes in Pregnant Women Exposed to QUVIVIQ®
RECRUITING
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04750616 · 304 participants · Phase 2
NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial
- NCT04994717 · 304 participants · Phase 3
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
- NCT06036147 · 304 participants · NA
Concussion Health Improvement Program
- NCT06096844 · 304 participants · Phase 3
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia